MARKET

INBX

INBX

Inhibrx, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.00
-2.87
-13.12%
Closed 16:00 10/28 EDT
OPEN
21.69
PREV CLOSE
21.87
HIGH
21.69
LOW
18.97
VOLUME
57.84K
TURNOVER
--
52 WEEK HIGH
26.98
52 WEEK LOW
15.42
MARKET CAP
677.44M
P/E (TTM)
-13.1798
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7)
Benzinga · 10/08 11:52
Credit Suisse Initiates Coverage On Inhibrx with Outperform Rating, Announces Price Target of $26
Credit Suisse initiates coverage on Inhibrx (NASDAQ:INBX) with a Outperform rating and announces Price Target of $26.
Benzinga · 09/14 09:09
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
The Daily Biotech Pulse: Modrerna Japanese Vaccine Deal Talk, Lipocine FDA Decision, Liver Congress Presentations
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 27)
Benzinga · 08/28 12:26
Oxford Finance Announces $10 Million Credit Facility with Inhibrx, Inc.
Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide, has announced that on July 15, 2020, it closed a $10 million senior secured term loan with Inhibrx, Inc. (or "the Company") (Nasdaq: INBX
PR Newswire · 08/25 17:17
Oxford Finance announces $10M credit facility with Inhibrx
Oxford Finance, a specialty finance firm, has closed a $10M senior secured term loan with Inhibrx ([[INBX]] -3.2%) on July 15.The funds, which were secured prior to the Company's recent
Seekingalpha · 08/25 16:33
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Data, Sorrento To Buy R&D Partner, Kymera IPO
  Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 20)
Benzinga · 08/21 11:43
Inhibrx gives back some of its IPO pop, -8%
Recent IPO Inhibrx is giving up nearly half of its debut gains on its second day of trading.The company priced 7M shares yesterday at $17/share, the midpoint of its expected
Seekingalpha · 08/20 14:56
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INBX. Analyze the recent business situations of Inhibrx, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INBX stock price target is 31.33 with a high estimate of 36.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 35.65M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Mark Lappe
Co-Founder/Executive Vice President/Chief Scientific Officer/Director
Brendan Eckelman
Co-Founder/Executive Vice President
Quinn Deveraux
Chief Financial Officer/Primary Contact
Kelly Deck
Executive Vice President
Klaus Wagner
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About INBX
Inhibrx Inc. is a clinical-stage biotechnology company. The Company is focused on developing biologic therapeutics for people with life-threatening conditions. It has a pipeline of novel biologic therapeutic candidates, developed using its single domain antibody (sdAb) platform. Its pipeline includes INBRX-109, INBRX-106, INBRX-105 and INBRX-101. INBRX-109 is a tetravalent death receptor 5 (DR5) agonist being evaluated in patients diagnosed with chondrosarcoma and mesothelioma cancers. INBRX-106 is a hexavalent OX40 agonist being investigated in patients with locally advanced or metastatic solid tumors. INBRX-105 is a precisely engineered tetravalent sdAb based therapeutic candidate, acting both as an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB. INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein therapeutic candidate, in development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Inhibrx Inc stock information, including NASDAQ:INBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INBX stock methods without spending real money on the virtual paper trading platform.